Literature DB >> 8315017

Application of low-avidity immunoglobulin G studies to diagnosis of Epstein-Barr virus infectious mononucleosis.

F de Ory1, J Antonaya, M V Fernández, J M Echevarría.   

Abstract

Single serum samples from 121 patients suffering from clinical infectious mononucleosis were tested by an indirect immunofluorescence assay for avidity of Epstein-Barr virus (EBV) capsid antigen immunoglobulin G (IgG), involving a wash step with phosphate-buffered saline-8 M urea. Ninety-four samples showed serological markers of recent EBV infection (presence of viral-capsid antigen-specific IgM [87 cases] and/or presence of IgG in the absence of EBV nuclear antigen antibodies [85 cases]). The remaining 27 cases had serological evidence of prior infection (presence of viral-capsid IgG and EBV nuclear antibodies and absence of IgM). In the avidity assay, 89 samples from patients with recent infection showed low-avidity IgG and 25 samples from patients with prior infection had high-avidity IgG. The avidity assay showed a sensitivity that was at least equal to those of classical serological procedures for diagnosing EBV infectious mononucleosis. Further studies are necessary, however, to establish the specificity of the assay and the duration of low-avidity antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8315017      PMCID: PMC265605          DOI: 10.1128/jcm.31.6.1669-1671.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Antibody avidity following varicella-zoster virus infections.

Authors:  H O Kangro; S Manzoor; D R Harper
Journal:  J Med Virol       Date:  1991-02       Impact factor: 2.327

2.  Studies on the control of antibody synthesis. 3. Changes in heterogeneity of antibody affinity during the course of the immune response.

Authors:  T P Werblin; Y T Kim; F Quagliata; G W Siskind
Journal:  Immunology       Date:  1973-03       Impact factor: 7.397

3.  Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis.

Authors:  G Henie; W Henle; C A Horwitz
Journal:  J Infect Dis       Date:  1974-09       Impact factor: 5.226

4.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

Review 5.  Detection of antiviral IgM antibodies and its problems--a review.

Authors:  O Meurman
Journal:  Curr Top Microbiol Immunol       Date:  1983       Impact factor: 4.291

6.  Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity.

Authors:  N K Blackburn; T G Besselaar; B D Schoub; K F O'Connell
Journal:  J Med Virol       Date:  1991-01       Impact factor: 2.327

7.  Measurement of avidity of specific IgG for verification of recent primary rubella.

Authors:  K Hedman; S A Rousseau
Journal:  J Med Virol       Date:  1989-04       Impact factor: 2.327

8.  Recent primary toxoplasma infection indicated by a low avidity of specific IgG.

Authors:  K Hedman; M Lappalainen; I Seppäiä; O Mäkelä
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

9.  Recent rubella virus infection indicated by a low avidity of specific IgG.

Authors:  K Hedman; I Seppälä
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317

10.  Persistence of specific IgM and low avidity specific IgG1 following primary rubella.

Authors:  H I Thomas; P Morgan-Capner; G Enders; S O'Shea; D Caldicott; J M Best
Journal:  J Virol Methods       Date:  1992-09       Impact factor: 2.014

View more
  9 in total

1.  Reliability of low-avidity IgG and of IgA in the diagnosis of primary infection by rubella virus with adaptation of a commercial test.

Authors:  J Gutiérrez; M J Rodríguez; F De Ory; G Piédrola; M C Maroto
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Epstein-Barr virus (EBV) DNA in sera of patients with primary EBV infection.

Authors:  K H Chan; M H Ng; W H Seto; J S Peiris
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

Review 3.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

4.  Differentiation of primary from nonprimary genital herpes infections by a herpes simplex virus-specific immunoglobulin G avidity assay.

Authors:  M Hashido; S Inouye; T Kawana
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

5.  Reliability of four methods for the diagnosis of acute infection by Epstein-Barr virus.

Authors:  J Gutiérrez; M Rodríguez; C Maroto; G Piédrola
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

6.  Application of a commercial immunoblot to define EBV IgG seroprofiles.

Authors:  Fernando de Ory; Eulalia Guisasola; David Tarragó; Juan Carlos Sanz
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

7.  Clinical reliability of IgG, IgA, and IgM antibodies in detecting Epstein-Barr virus at different stages of infection with a commercial nonrecombinant polyantigenic ELISA.

Authors:  J Gutiérrez; M J Vergara; G Piédrola; M C Maroto
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

8.  Evaluation of an immunofiltration assay that detects immunoglobulin M antibodies against the ZEBRA protein for the diagnosis of Epstein-Barr virus infectious mononucleosis in immunocompetent patients.

Authors:  Dayana Bravo; Beatriz Muñoz-Cobo; Elisa Costa; M Angeles Clari; Nuria Tormo; David Navarro
Journal:  Clin Vaccine Immunol       Date:  2009-04-29

9.  Relationship between herpes simplex virus-1-specific antibody titers and cortical brain damage in Alzheimer's disease and amnestic mild cognitive impairment.

Authors:  Roberta Mancuso; Francesca Baglio; Simone Agostini; Monia Cabinio; Maria M Laganà; Ambra Hernis; Nicolò Margaritella; Franca R Guerini; Milena Zanzottera; Raffaello Nemni; Mario Clerici
Journal:  Front Aging Neurosci       Date:  2014-10-15       Impact factor: 5.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.